AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer... (ent Board the training programme seeks t...)

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds

Date:8/14/2008

ent Board, the training programme seeks to train a pool of clinical research professionals for both private-sector and public-sector research labs.

"Singapore is one of Asia's fastest growing bio-clusters and offers excellent IP protection, a population base representative of Asia, world-class scientific and clinical infrastructure as well as access to global talent," said Mr. Yeoh Keat Chuan, Executive Director, Biomedical Sciences, Singapore Economic Development Board. "AstraZeneca joins an expanding base of leading pharmaceutical and biotechnology companies that have chosen to develop new drugs and therapies in Singapore. It is a strong testament of Singapore's capabilities in translational and clinical research, particularly in applications for diseases prevalent in Asia."

National Healthcare Group (NHG) Chief Executive Officer, Dr. Lim Suet Wun says, "165 out of 1,069 ongoing research studies in NHG focus on Oncology. The collaboration with AstraZeneca will provide an excellent platform for our researchers and research support team to access renowned expertise and facilities at the Manchester Cancer Research Centre, all with the aim to develop impactful outcomes for cancer patients."

Caroline Shaw, Chief Executive of the Christie Hospital, a founding partner of Manchester Cancer Research Centre together with The University of Manchester and Cancer Research UK said "The Christie Hospital is world renowned for its radiation related research and investigative clinical trials. We are proud that the quality of our training in these disciplines is recognised and has been assimilated as a foundational activity in this exciting partnership with Asia"

Under the terms of the clinical development collaboration, two of Singapore's leading research institutions -- the NCCS and NUH -- will be given access to AstraZeneca compounds which have already undergone initial clinical testing in the West.

Two AstraZeneca compounds(3), have already be
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
10. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination

Post Your Comments:

(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab

(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,

(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square

Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3 AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1 AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 1 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 2 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 3 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 4 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 5 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 6 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 7 Child Food Allergies on the Rise in U S 61410 1 Child Food Allergies on the Rise in U S 61410 2 Child Food Allergies on the Rise in U S 61410 3

[0] US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder [0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects [0] BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark

...nificant Reduction in Relapse Rate , , - Secondar... of Patients Relapse-Free and Disability Progressi...e Tablets Planned for mid-2009 , , SEATTLE and GE...KGaA, announced today detailed results of the two-... III trial using Cladribine Tablets (Merck Serono,...

...y and safety for extended release and immediate re...ril 29 /PRNewswire/ -- New findings from two dou...ty and tolerability of pramipexole dihydrochloride...ation, for the treatment of Parkinson,s disease (P...emy of Neurology (AAN) 61st Annual Meeting in Seat...

Other Medicine Technology:Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 2 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 3 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 4 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 5 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 6 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 7 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given

(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for

(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W

(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s

[0] Salon Leau to Host 'Cuts for a Cause' to Raise Funds and Spread the Word About Childhood Terminal Illnesses [0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification [0] Distributor Announces New Applications for Wind Turbines [0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children

...daq: XTNT ) today reported financial results for ...7., The company reported a net loss and net loss ...on, or $0.52 per share, for the fourth quarter,of ...mpany,s net loss per share attributable to common ...

... same results, analysis shows , , TUESDAY,...cular advantage to any single treatment for acute ...ion that carries with it a high risk of death, Can...or another, according to a report in the Feb. 20 ...

... way to spot hearing problems, study finds, , ...s may not just be a window to the soul, they may a...r senses. , A new study reports that the eyes can ... young children and in people who can,t actively t...

...tive isotopes for peacetime uses at Oak Ridge Nati...al Historic Chemical Landmark by the American Chem...enn., on March 6. , Bruce E. Bursten, Ph.D., pre...s, which began in 1946, demonstrated the peaceful ...

... Hospital, WALLA WALLA, Wash., Feb. 19 Secretary...today the Department of,Veterans Affairs (VA) will...on facility focused on mental health at the Walla ...ortance of mental,health as an issue for our veter...

...ered physical or sexual abuse as children spend up...ts, according to a long-term study of more than 3,...these women used health services at significantly ...quences from abuse that occurred decades ago, said...

Other Medicine News:Health News:XTENT Announces 2007 Financial Results 2 Health News:XTENT Announces 2007 Financial Results 3 Health News:XTENT Announces 2007 Financial Results 4 Health News:XTENT Announces 2007 Financial Results 5 Health News:XTENT Announces 2007 Financial Results 6 Health News:No Difference Found in Treatments for Acute Kidney Failure 2 Health News:No Difference Found in Treatments for Acute Kidney Failure 3 Health News:Eyes a Window to Hearing Loss? 2 Health News:Eyes a Window to Hearing Loss? 3 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3 Health News:Women who suffered child abuse spend more on health care 2 Health News:Women who suffered child abuse spend more on health care 3

XTENT Announces 2007 Financial Results No Difference Found in Treatments for Acute Kidney Failure Eyes a Window to Hearing Loss?Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark VA Secretary Announces New Walla Walla Facility Women who suffered child abuse spend more on health care

Full Body Girdle V-1655

Body Suit w/Bra above knee, Front Closure

Compression Vest V-640

Male Compression Vest Binder

Medicine Products:

Full Body Girdle V-1655 Body Suit w/Bra above knee, Front Closure Compression Vest V-640 Male Compression Vest Binder

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer...(ent Board the training programme seeks t...),Health